Project Grant K99HL173656
Award Date
8/1/24
Completion Date
7/31/26
Dollars Obligated
$157K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Philadelphia, PA 19104, USA
Similar Awards
This $480,990 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) Cardiovascular Diseases Research program (CFDA 93.837) supports research on the role of aerocytes, a specialized capillary endothelial cell population, in alveolar epithelial regeneration following acute lung injury. The research aims to investigate how aerocyte-derived signaling, particularly the R-spondin3 molecule, guides the regenerative remodeling of alveolar epithelium and establishes a...
This Project Grant award of $148,568.00 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research by Mayo Clinic to investigate the role of pleural mesothelial cells in lung injury, repair, and regeneration. The study aims to provide a detailed understanding of the signaling and functional roles these cells play in the contexts of lung injury, fibrosis, and repair, using lineage-tracing experiments and genomic analysis. The research...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $186,857 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to Duke University to study the role of TP53 regulation in alveolar epithelial transitional cell state and its contribution to pulmonary fibrosis. The research aims to uncover the molecular mechanisms that regulate alveolar epithelial cell states and determine the impact of an alveolar epithelial transition state on the pathogenesis of pulmonary fibrosis, a...
This $684,814 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) supports research on how lung stromal factors and tissue-resident lymphocytes suppress alveolar stem cells in emphysema. The research aims to elucidate the mechanism by which stromal factors modify the inflammatory response to viral infections and tobacco smoke, and how this leads to suppression of alveolar type 2 stem cells in both mouse and human models. The...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,564,220.00 to The Trustees of the University of Pennsylvania (doing business as Clinical Practices of the University of Pennsylvania) to develop an imaging-compatible ex vivo lung perfusion (EVLP) system. The goal is to obtain structural, functional, and metabolic biomarkers that can be used to assess and recondition...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $777,048 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The Trustees of Columbia University in the City of New York, Health Sciences Division. The grant will fund research focused on enhancing host resilience against acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) through the induction of myeloid-epithelial gap junctional channels. The research aims to evaluate the extent to which...
This $123,000 Project Grant was awarded on February 1, 2025 by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837). The grant supports a research project investigating the role of the Hedgehog signaling pathway in regulating differentiation timing of lung progenitor cells, both in normal lung development and in the context of two major lung diseases - chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $161,240 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The General Hospital Corporation (Massachusetts General Hospital) to investigate endothelial S1PR1 signaling pathways that promote lung repair after viral respiratory infections leading to acute respiratory distress syndrome (ARDS). The 5-year grant, effective August 1, 2024, aims to define the mechanisms by which endothelial S1PR1 supports...
This Project Grant award, funded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), supports research to investigate the impact of aging and metabolic dysfunction on alveolar epithelial progenitor cell function in pulmonary fibrosis. The award of $162,540 will be provided to the Trustees of the University of Pennsylvania, doing business as the Clinical Practices of the University of Pennsylvania, over a 2-year period from...
The federal Cooperative Agreement U01HL175409, awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), provides $798,727 to The Trustees of the University of Pennsylvania to conduct research focused on defining the cellular and molecular changes that occur in chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and rare diseases like alpha-1 antitrypsin deficiency.
The research aims to: 1)...